Abstract
Non-Muscle invasive urothelial carcinoma is a variable disease that needs a variety of surgical and non-surgical treatment strategies (Neuzillet et al. in Prog Urol 22(16):989–998, 2012). The disease course can range from recurrent low-grade papillary disease to aggressive disease concerning for progression from initial presentation (Neuzillet et al. in Prog Urol 22(16):989–998, 2012). This chapter relates to adverse effects in BCG therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Neuzillet Y, Rouprêt M, Larré S, Irani J, Davin JL, Moreau JL, Pfister C. Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC). Presse Med. 2013;42(7–8):1100–8.
Neuzillet Y, Rouprêt M, Wallerand H, Pignot G, Larré S, Irani J, Davin JL, Moreau JL, Soulié M, Pfister C, le comité de cancérologie de l’association française d’urologie. Diagnosis and management of adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the cancer committee of the French association of urology. Prog Urol. 2012;22(16):989–98.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Persad, R., Motiwala, H., Albala, D. (2020). Adverse Effects in BCG Therapy. In: Management of Non-Muscle Invasive Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28646-0_32
Download citation
DOI: https://doi.org/10.1007/978-3-030-28646-0_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28645-3
Online ISBN: 978-3-030-28646-0
eBook Packages: MedicineMedicine (R0)